- Quotes
- Dashboard
- Chart
- Historical Prices
- Options
- News & PR
- News
- Market Currents
- Press Releases
- Coverage
- Cramer
- Top Analysts
- Business Intelligence
- Transcripts
- Events
- Key Developments
- Earnings
- History & Projected
- Consensus
- Peer Earnings
- Filings
- SEC Filings
- Annual Report
- Financials
- Income Statement
- Balance Sheet
- Cash Flow
52wk high:
52wk low:
EPS:
PE:
Div Rate:
Yield:
Market Cap:
Volume:
PCYC Market Currents
more »
-
April 11 Pharmacyclics (PCYC +3.8%) trades higher after the FDA designates Orphan Drug Status for its chronic lymphocyctic leukemia treatment.
1 Comment[On the Move, Healthcare]
PCYC in Focus
more »
PCYC Related Articles
more »
PCYC News
more »
-
at MarketWatch.com (May 2, 2012)
-
at MarketWatch.com (Mar 20, 2012)
-
at CNBC.com (Jan 26, 2012)
-
at MarketWatch.com (Jun 16, 2010)
PCYC Press Releases and Filings
more »
-
PR Newswire (Tue, 6:00AM)
-
PR Newswire (May 17, 2012)
-
PR Newswire (May 10, 2012)
-
PR Newswire (Dec 19, 2011)
-
PR Newswire (Dec 13, 2011)
PCYC Latest Transcript
more »
Currently, there are no transcripts for PCYC.
PCYC Cramer
more »
PCYC Instablog posts
more »
PCYC vs. ETF Alternatives
Company Description
We are a clinical-stage biopharmaceutical company focused on developing and commercializing innovative small-molecule drugs for the treatment of immune mediated disease and cancer. Our purpose is to create a profitable company by generating income from products we develop, license and... More
